Alliance Global raised the firm’s price target on Trulieve Cannabis (TCNNF) to C$27 from C$19 and keeps a Buy rating on the shares. The firm views the company’s Q1 report as “clean.” Trulieve is a “strong beneficiary of medical rescheduling,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCNNF:
- Analyst Reiterates Buy on Trulieve, Maintains $19 Price Target on Strong Profitability and Cash Generation
- Trulieve Cannabis Posts Profitable Q1 2026, Expands Footprint
- Roth views partial cannabis re-scheduling order as ‘extremely favorable’
- Trump Trade: Trump officials reclassify state-licensed medical marijuana
- Trump administration reclassifies state-licensed medical marijuana